A Prospective Controlled Study of Magnetic Resonance Imaging of the Brain in Gay Men and Parenteral Drug Users with Human Immunodeficiency Virus Infection by Dooneief, George et al.
A Prospective Controlled Study of Magnetic Resonance
Imaging of the Brain in Gay Men and Parenteral Drug
Users With Human Immunodeficiency Virus Infection
George Dooneief, MD; Jacqueline Bello, MD; George Todak, MSW; In K. Mun, PhD; Karen Marder, MD;
Ren\l=e'\eMalouf, MD; Jack Gorman, MD; Sadek Hilal, MD, PhD; Yaakov Stern, PhD; Richard Mayeux, MD
\s=b\To detect the earliest structural changes
in the brain in human immunodeficiency vi-
rus (HIV) infection, 118 gay men and 115 par-
enteral drug users enrolled in a study of the
natural history of HIV infection underwent
magnetic resonance imaging evaluations.
RoutineT2-weighted and heavily T2-weighted
scans for quantification of brain water were
obtained, blinded to HIV serostatus. Atrophy
and foci of increased signal did not correlate
with any medical, immunologic, neurologic,
or neuropsychologic parameters in the
group as a whole, or in the gay men or paren-
teral drug user subgroups. Three subjects
had progressive multifocal leukoencephalo-
pathy and one had central nervous system
lymphoma. In a subgroup in whom intracra-
nial water percent was calculated, correla-
tions were found with CD4 counts and
CD4/CD8 ratios. We conclude that standard
magnetic resonance imaging of the brain
does not differentiate asymptomatic and
mildly symptomatic HIV-positive individuals
from HIV-negative individuals, regardless of
risk group. However, intracranial water per-
cent may distinguish HIV-positive from HIV\x=req-\
negative individuals because it correlates
with raw CD4 counts and CD4/CD8 ratios.
{Arch Neurol. 1992;49:38-43)
  / agnetic resonance imaging (MRI) ofthe brain in patients with acquired
immunodeficiency syndrome (AIDS)
with neurologic signs or symptoms has
demonstrated atrophy, white matter
changes, and mass lesions." Clinical
progression and abnormalities on sub¬
sequent scans have been predicted by
brain atrophy noted on computed tomo¬
graphic scans of patients with AIDS.1
We developed a quantitative measure of
atrophy in MRI in an attempt to detect
the earliest structural change in the hu¬
man immunodeficiency virus (HlV)-in-
fected brain and its relationship to medi¬
cal, neurologic, and neuropsychologic
manifestations of HIV disease.
SUBJECTS AND METHODS
Subjects
Subjects being followed up in a prospective
study of the natural history of HIV infection
that began in March 1988 (the follow-up
study8) were recruited to participate in an
MRI study that began in September 1989.
The original study group consisted of volun¬
teers from gay men's organizations, an infec¬
tious disease clinic, and a methadone mainte¬
nance clinic and were solicited through
newspaper advertisements and by word of
mouth.
Inclusion criteria for the larger follow-up
study from which our subjects were recruit¬
ed were as follows: (1) age between 18 and 60
years, (2) gay or bisexual man without self-
administration of parenteral drugs more
than 10 times since 1982 (gay men cohort) or
history of parenteral drug use at least 10
times since 1982 (parenteral drug user[PDU1 cohort), (3) prior knowledge of HIV
status, and (4) proficiency in English.
Exclusion criteria were as follows: (1) the
Centers for Disease Control National Sur¬
veillance Criteria for AIDS at the time of
enrollment, with the exception of AIDS de¬
mentia and esophageal candidiasis; (2) pres¬
ence of an encephalopathy unrelated to HIV
infection (eg, posttraumatic dementia), and(3) presence of a chronic neurologic disorder
antedating HIV infection (eg, epilepsy re¬
quiring continuing therapy).
Three hundred eighty-two subjects were
in the follow-up study at the beginning of the
MRI study. Two hundred thirty-seven were
scanned between September 1989 and Au¬
gust 1990. Of the remaining 145 subjects, 56
refused the test, 32 were unable to undergo
the procedure because of claustrophobia, 10
were incarcerated, nine died, eight dropped
out of the study, seven were excluded be¬
cause of metal implants, four could not be
scanned because of machine breakdown or
maintenance, four had inadequate or incom¬
plete scans, and 15 subjects could not be
located.
The biannual assessments in the follow-up
study have been described in detail else¬
where8'" and are summarized below.
Medical Evaluation
Medical evaluation included complete
blood cell count, CD4 and CD8 counts, and a
physical examination performed by a physi¬
cian "blind" to the subject's HIV status. Re¬
view of these data allowed the classification
of each subject as HIV-negative, HIV-posi¬
tive asymptomatic, and HIV-positive with
mild symptoms (primarily enlarged lymph
nodes), with AIDS-related complex, or with
AIDS.
Neurologic Evaluation
All neurologic evaluations were performed
by neurologists blinded to HIV serostatus.
Constellations of signs associated with the
central and peripheral nervous system were
assessed to rate impairment in nine catego¬
ries of neurologic function: mental (as as¬
sessed by a brief 19-item mental status test),
visual (scotoma or diminished acuity), brain
stem (nystagmus, extraocular muscle weak¬
ness, or dysarthria), pyramidal (deficient
rajad alternating movements, paraparesis,
or hemiparesis), extrapyramidal (rigidity,
bradykinesia, or tremor), cerebellar (atax¬
ia), sensory (vibratory loss or stocking/glove
neuropathy), bowel/bladder (urgency or in¬
continence), and peripheral nerve (weak¬
ness, pain, or sensory loss in an asymmetric
distribution, excluding stocking/glove
neuropathy).
A summary score was calculated based on
a modified version of the Kurtzke Disability
Status Scale for Multiple Sclerosis " to reflect
the overall degree of neurologic disability.
Neuropsychologic Evaluation
Neuropsychologic testing was also per¬
formed blinded to serostatus. All subjects
underwent tests of general intelligence (a
modified version of the Mini-Mental State
examination '), abstract reasoning (the
Wechsler Adult Intelligence Scale-Revised[WAIS-R1 similarities subtest'2), verbal and
nonverbal memory (the Selective Reminding
test13 and the Wechsler Memory Scale-Re¬
vised [WMS-R1 visual reproduction sub-
test"), language (the Boston Naming test,1"
the Controlled Oral Word Association test,1"
and the Sentence Repetition subtest of the
Boston Diagnostic Aphasia Examination1'),
executive function (the Odd-Man-Out test18
and the Trail Making test
'
), visuosj^atial
ability (the WAIS-R Block Design subtest12),
and attention (two cancellation tasks,20 the
WAIS-R Digit Symbol subtest,12 and the
WAIS-R Digit Span subtest12). In addition,
the gay men underwent the conceptual levels
and analogies test,21 the Benton Visual Re¬
tention test,22 the Stroop Color-Word test,23
the Benton Line Orientation test,24 a 24-item
version of the Raven's Progressive Matri¬
ces,
 
and a 20-trial choice reaction time task.
Performance on each test was compared
with norms for age- and education-matched
populations and then rated as normal, bor¬
derline (at least 1 SD below expected mean),
or defective (at least 2 SDs below the expect¬
ed mean). A global performance rating(GPR) was derived to summarize overall
neuropsychologic performance with resjpect
to these norms. On this scale, a score of0 was
given for normal performance on all tests, a
score of 1 for borderline performance in one
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or more areas, a score of 2 for defective per¬
formance in one area, a score of 3 for defec¬
tive performance in two or more areas exclu¬
sive of memory, and a score of4 for defective
performance in memory and two or more
other areas.
A clinical impression of neuropsychologic
performance (0, normal; 1, borderline; or 2,
abnormal) was generated based on a consen¬
sus of otMnion of two experienced neuropsy-
chologists who reviewed the test scores inde¬
pendently and who were blinded to the
serostatus.
MRI
Scans were performed on a 1.5-tesla sys¬
tem. The imaging protocol consisted of T2-
weighted axial and coronal scans(TR = 3500 and TE = 80), with a slice
thickness of 5 mm and a 4 mm gap. Images
were acquired on a 512  512 matrix. An
additional heavily T2-weighted scan(TR = 7100 and TE = 280) was obtained in
the axial plane only, for quantification of
brain water.
In a small pilot study before this investiga¬
tion began, there was complete concordance
between two neuroradiologists (J.B. and
S.H.) in their assessment of degree of atro¬
phy, presence of high signal foci, and otherlesions.
In the present study, standard T2-weight-
ed scans were evaluated by a single neurora-
diologist (J.B.) who took into account each
subject's age but was blinded as to their sero¬
status and other clinical details. Scan quality
was rated as excellent, adequate, inade¬
quate, or incomplete, and only data from ex¬
cellent or adequate scans were included in
the analysis. Atrophy, small areas of high
signal intensity, larger focal lesions, and oth¬
er abnormalities were recorded.
Atrophy was rated as absent, mild, moder¬
ate, or marked for each subject's age (Figs 1
through 3). Focal atrophy was scored as
present or absent for each cerebral lobe, the
sylvian fissures, brain stem, cerebellar hemi¬
spheres, and vermis. If atrophy was only
cortical (ie, sulcal enlargement without ven¬
tricular enlargement), this was also noted.
For a scan to receive a rating of moderate
atrophy, both the sulcal prominence and the
ventricular size had to, in the estimation of
the neuroradiologist, be sufficient to suggest
that this was a normal scan for a person
approximately 20 years older than the sub¬ject's age. Scans with sulcal prominence and
ventricular size deemed abnormal for a per¬
son 20 years older than the subject were
rated marked atrophy. On the other hand,
the presence of focal atrophy or diffuse atro¬
phy to any lesser degree received a designa¬
tion of mild atrophy. Consequently, this last
category included a wide spectrum of scans.
Small foci of high-signal intensity (3 mm or
greater and less than 2 cm) were rated as
absent, single, few (less than five and less
than two confluent), multiple (five or greater
or two confluent), or diffuse (many confluent
or foci of 2 cm or greater), and their number
and locations were recorded (Fig 1). Differ¬
entiating small high-signal foci from cerebro¬
spinal fluid (CSF) spaces was problematic
with the standard pulse sequence. There¬
fore, we required a high-signal focus to be
seen in both axial and coronal planes, clearly
Fig 1.—Axial T2-weighted image of a 37-year-
old subject without atrophy. Two periventricular
foci of increased signal are noted.
Fig 2.—Axial T2-weighted image of a 39-year-
old subject with moderate atrophy.
Fig 3. —teft, Axial T2-welghted image of a 39-year-old subject with mild atrophy. Right, Heavily T.¿
weighted image of the same scan section as in the image on the left.
separated from sulci, cisterns, and the ven¬
tricular system.
Larger focal lesions consistent with oppor¬
tunistic infections or neoplasms were also
noted, as were other abnormalities (eg, arte¬
riovenous malformations, strokes, or
sinusitis).
The percentage of the intracranial cavity
occupied by the CSF was quantitated using
the heavily T2-weighted scans (Fig 3). These
images demonstrate a bright signal generat¬
ed by protons in water molecules with a very
long T, (eg, within the CSF, globes, and
inflamed sinuses), and essentially no signal is
generated by the brain or other soft tissue. A
cursor was used to trace the inner table of the
skull in each scan section. The maximum
brightness (corresjjondingto an area of CSF)
within the traced area was scaled by comput¬
er to a value of 255. If a given pixel contained
CSF only, it was given a value of 255 and if
there was a partial volume effect, the value
was scaled in proportion to the amount of
brain sharing the pixel with the CSF. If the
entire pixel contained only brain, the value
was 0. Software was developed to calculate
the area within the outlined region ofinterest
and also the total signal within this perime¬
ter. The proportion of the intracranial cavity
consisting of CSF was computed by adding
the total signal from each scan section and
dividing by the total area within the scan
multiplied by 255, ie,
(Scaled Pixel Values Within Traced
Regions)/[(Pixels Within Traced Regions)  255]
= Proportion CSF
To validate this technique, "phantom"
studies using objects suspended in water
demonstrated greater than 95% accuracy of
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MRI-calculated volumes compared with
measured volumes; reproducibility was bet¬
ter than 97%.
Subjects whose MRI scans demonstrated
a lesion believed to warrant further investi¬
gation were contacted by the study coordina¬
tor, and the scans were discussed with one of
the study neurologists.
Data Analysis
Analysis of variance and statistical meth¬
ods for rates and proportions were used to
compare characterisitics of the variousgroups.262' In the initial analysis, summary
measures were used for the medical, neuro¬
logic, and neuropsychologic parameters to
reduce the number of comparisons and
strengthen the relationships found to be sta¬
tistically significant. It would also decrease
the likelihood of chance associations (ie,
there would be a tendency toward type II
rather than type I error).
Thus, we used  2 tests for ordered/cate¬
gorical data collapsed into two categories(eg, normal vs abnormal and present vs ab¬
sent) to look at the relationships among atro¬
phy, white-matter signal hyperintensities(WMH), overall neurologic disability, global
neuropsychologic performance, clinical neu¬
ropsychologic impression, and HIV serosta¬
tus in the group as a whole, as well as in a
variety of subgroups, ie, HIV-positive, HIV-
negative, gay men, PDUs, HIV-positive gay
men, HIV-negative gay men, HIV-positive
PDUs and HIV-negative PDUs. To assess
group differences for interval data (age, edu¬
cation, CD4 count and CD4/CD8 ratio) in
independent groups (HIV-positive/HIV-
negative, gay men/PDUs, HIV-positive gay
men/HIV-negative gay men, HIV-positive
PDUs/HIV-negative PDUs, HIV-positive
gay men/HIV-positive PDUs, HIV-negative
gay men/HIV-negative PDUs, WMH pre-
sent/WMH absent, and atrojihy absent or
mild/atrophy moderate or marked), we em¬
ployed a t test for independent samples and
analysis of variance. Pearson correlations for
interval data (age, CD4, CD4/CD8 ratio, in¬
tracranial water percent [%CSF]), and also
partial correlations controlling for age were
performed in the group as a whole, as well as
in a variety of subgroups. Last, to assess
group differences in %CSF, analyses of co-
variance (controlling for age) were per¬
formed with respect to stage, cohort, WMH,
atrophy, and HIV serostatus.
RESULTS
The subjects are described in Tables 1
and 2. There were no significant differ¬
ences in age, education, GPR, clinical
neuropsychologic impression, or overall
neurologic disability between the HIV-
positive and HIV-negative subjects.
The baseline neurologic and neuropsy¬
chologic data in the gay men cohort are
described elsewhere,9 and the baseline
PDU data have been submitted for pub¬
lication. The raw data are available on
request.
The scan results are displayed in Ta¬
bles 3 and 4. Ninety-seven percent of
the scans revealed at least a mild degree
of atrophy (77% mild and 20% moder-
Table 1.—Study Subjects Stratified by Risk Group and Serostatus*
Gay Men PDUs
All All HIV+ HIV- All HIV+ HIV-







































































































*PDUs indicates parenteral drug users; HIV, human Immunodeficiency virus; plus and minus signs, positive
and negative, respectively; star, missing data; GPR, global neuropsychologic performance rating; Neurlmp, clin¬
ical neuropsychologic impression; and Kurtzke, a measure of overall neurologic disability modified from the
Kurtzke Disability Status Scale for Multiple Sclerosis.'0 Numbers In parentheses are SDs.
Table 2.—Study Subjects Stratified by Risk Group and Clinical Stage*
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448.5 493.7 354.1 20.00 935.6 537.6 351.3 324.1 266.8
(188) (326) (292) (19.9) (322) (114) (213) (229) (78)
CD4/CD8 1.40 0.63 0.67 0.41 0.04
ratio (0.4) (0.3) (0.4) (0 4) (0.0)
1.39 0.65 0.44 0.36 0.38
(0.5) (0.3) (0.3) (0.2) (0.2)
*PDUs Indicates parenteral drug users; GPR, global performance rating; Neurlmp, clinical neuropsycholog¬
ical impression; Kurtzke, overall neurological disability. Numbers in parentheses are SDs. Stage 0 indicates hu¬
man immunodeficiency virus (HIV) negative; 1, HIV positive, asymptomatic; 2, HIV positive, with mild symptoms(eg, enlarged lymph nodes); 3, acquired immunodeficiency syndrome-related complex; and 4, acquired immu¬
nodeficiency syndrome.
ate). This preponderance of mild atro¬
phy, even among the HIV-negative
subjects, was surprising. In part, it may
stem from the subjective criteria used
for assessing atrophy. As a result of the
schema outlined in the "Subjects and
Methods" section, cases with mild or no
atrophy were grouped together and
contrasted with moderate or marked at¬
rophy. Foci of increased signal on the
T2-weighted images were noted in 20%
of cases. Eight subjects had other ab¬
normalities on their scans. In four,
these were consistent with AIDS-relat-
ed illnesses (three cases of progressive
multifocal leukoencephalopathy and
one case of CNS lymphoma), and in the
other four cases the abnormalities were
believed to be unrelated to AIDS (two
cerebral infarctions, one arteriovenous
malformation, and one para-atrial cho-
roid fissure cyst).
In the standard T2-weighted scans,
we examined the relationships between
atrophy and WMH and the medical,
neurologic and neuropsychologic data
first in the entire group and then in the
following subgroups: HIV-positive sub¬jects, HIV-negative subjects, gay men,
PDUs, HIV-positive gay men, HIV-
negative gay men, HIV-positive PDUs,
and HIV-negative PDUs.
In the group as a whole, atrophy was
not related to GPR, the clinical neuro¬
psychologic impression, the overall de¬
gree of neurologic disability, CD4
count, or HIV serostatus. However,
moderate atrophy was more common in
the gay men than in the PDUs( 2 = 8.8,  = .003). There was no re¬
lationship between WMH and GPR,
clinical neuropsychologic impression,
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Table 3.—Results of Routine T2-Weighted MRI Scans in the Entire Group and Stratified
by Risk Group and Serostatus*
Gay Men PDUs

























* MRI indicates magnetic resonance imaging; HIV, human immunodeficiency virus; plus and minus signs, pos¬
itive and negative, respectively; PDUs, parenteral drug users; and star, missing data.














0 0 10 0 1
*MRI indicates magnetic resonance imaging; HIV, human Immunodeficiency virus; WMHs, white-matter sig¬
nal hyperintensities; stage 0, HIV negative; 1, HIV positive, asymptomatic; 2, HIV positive with mild symptoms
(eg, enlarged lymph nodes); 3, acquired immunodeficiency syndrome-related complex; 4, acquired immunode¬
ficiency syndrome; and star, missing data.
overall degree of neurologic disability,
CD4 count, or serostatus. The mean age
of subjects with WMH (43.0 years) was
significantly higher than that of sub¬jects without WMH (38.9 years)(i = 3.18,  = .002). There was no re¬
lationship between atrophy and WMH.
In the HIV-positive subjects, there
were no significant associations be¬
tween either atrophy or WMH and CD4
or CD8 counts, GPR, clinical neuropsy¬
chologic impression, or overall neuro¬
logic disability.
For the HIV-negative subjects,
WMH increased in frequency with atro¬
phy ( 2 = 4.7,  = .030), but there were
no other associations between MRI
variables and medical, neurologic, or
neuropsychologic variables.
No relationships existed between the
MRI findings and neurologic or neuro¬
psychologic variables in either the gay
men as a group or the PDU cohort.
There were no relationships between
the MRI findings and other variables in
the HIV-positive gay men, HIV-posi¬
tive PDU, and HIV-negative PDU
groups; however, WMH increased with
atrophy in the HIV-negative gay men( 2 = 4.8,  = .029).
A subgroup, the initial 50 subjects,
had %CSF calculations performed. Sub¬jects with inadequate or incomplete
scans and the eight subjects with focal
lesions were excluded from this sub¬
group (described in Table 5). As the
WMH were not visualized on the heavi¬
ly T2-weighted scans, they were not be¬
lieved to contribute to the %CSF calcu¬
lations, and these subjects were not
excluded from the analysis. Within this
subgroup, there were no differences be¬
tween the HIV-positive and HIV-nega¬
tive subjects with respect to age, educa-
Table 5.—Subgroup of Subjects With
Intracranial Water Percent (% CSF),




Age, y 41.8(8.5) 39.7(7.8)
Education, y 15.0(3.0) 14.0(3.3)
CD4, No./mm3 488.1(344) 578.1(385)
CD4/CD8 ratio 0.71 (0.6) 0.81 (0.6)




HIV+ gay men 23 75
HIV- gay men 4 38
HIV+ PDUs 8 54
HIV- PDUs 8 52
*HIV Indicates human immunodeficiency virus;
plus and minus signs, positive and negative, respec¬
tively; and PDUs, parenteral drug users. Numbers in
parentheses are SDs.
tion, GPR, clinical neuropsychologic
impression, overall neurologic disabil¬
ity, atrophy rating, or WMH. More¬
over, they did not differ from the sub¬jects without %CSF calculations with
respect to these factors. Intracranial
water percent correlated with age(r = .3763,  = .013) and the radiolo¬
gist's rating of atrophy (r = .5031,
 
=
.001). After controlling for age,
%CSF still correlated with the subjec¬
tive rating of atrophy (r = .5240,
 
=
.000), and there was a negative
correlation with both the CD4 count
(r=-.3959,  = .009) and the
CD4/CD8 ratio (r = -.3071,
 
=
.0488). Intracranial water percent
adjusted for age was not significantly
increased in the HIV-positive subjects
compared with the HIV-negative sub¬jects, nor were there any statistically
significant relationships between
%CSF and neurologic or neuropsycho¬
logic summary variables.
COMMENT
The frequency of neurologic involve¬
ment in AIDS has engendered numer¬
ous attempts to detect early neurologic
or neuropsychologic changes in HIV-
infected individuals who have not devel¬
oped AIDS. A number of studies have
demonstrated differences between
HIV-positive and HIV-negative sub-jects2""3"; others, a continuum of change
across stages31,32; and others, no differ¬
ences between seropositive and sero¬
negative subjects.33"35 In the follow-up
study, we noted slight impairment on
neuropsychologic tests associated with
subtle neurologic signs and symptoms
in the HIV-positive subjects that were
believed to be without functional conse¬
quence.9 The suggestion that there may
be subtle changes early in the course of
HIV infection raises the question of
whether or not there is a preceding or
concomitant structural CNS change
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Table 6.—Magnetic Resonance Imaging and HIV*
Source, y Atrophy WMHs Stage of Illness
Levy et al,1 1986 NA 5/6 AIDS, no controls
Shabas et al," 1987 1/1 AIDS, no controls
Grant et al/5 1988 23 9/13"; 5/10b 10/23·1 a indicates AIDS, b, ARC
Post et al,1 1988 6/7 AIDS, no controls
Ekholm and Simon,*6 1988 3/3 3/3 ARC, no controls
Olsen et al,3 1988 365 63/365 112/365 AIDS, no controls
Trotot et al,33 1988 15 NA 4/15 HIV+, no symptoms
Freund-Levi et al,47 1989
Subsequent scans
0/4 Seropositive only
3/3 1/3 AIDS (transfusion)t
MacArthur et al,7 1990 149 NA 18/62 HIV— gay men controls
33/128 HIV+ no symptoms*
3/17 HIV+ symptomatic
Levy et al,2 1990 50 6/50 2/50 AIDS, no controls
Kieburtz et al,41 1990 30/52 HIV+ no symptoms, 12;
ARC, 14; AIDS, 26
Kupfer et al,5 1990 130 44/130 AIDS, no controls
Chrysikopoulos et al,$ 1990 14 8/10 5/10 AIDS, no controls




Koralnik et al," 1990
Subsequent scans
62 0/33 1/33 HIV— gay men controls
1/29 0/29 HIV+ no symptoms
HIV+ no symptoms
Post et al," 1991 2/95 11/95 HIV+ no symptoms
HIV+ symptomatic
Present study 86/90 HIV-
138/143 28/143 HIV+
*HIV indicates human immunodeficiency virus; plus and minus signs, positive and negative, respectively;WMHs, white-matter signal hyperintensities; NA, not available; AIDS, acquired immunodeficiency syndrome;
ARC, AIDS-related complex; and CDC II, III, and IV, AIDS stages II, III, and IV, respectively, using the Centers
for Disease Control criteria.
tFour transfusion recipients with serial scans.
tRefers to medical or systemic symptoms, such as weight loss or fatigue, but without evidence of AIDS; ex¬
cludes patients with tumors or opportunistic infections.
that might be identified on MRI scans.
Aside from opportunistic infections
and neoplasms, the main focuses of ra¬
diologie studies in HIV disease have
been subcortical WMH on MRI and dif¬
fuse brain atrophy (Table 6). White-
matter signal hyperintensities have
been noted predominantly in the sub-
cortical and periventricular white mat¬
ter areas. Because these locations are
identical to those with pathologic
changes in the AIDS dementia com¬
plex,33" many believed that they might
represent early signs of direct HIV in¬
fection of the CNS.4'2* We noted no rela¬
tionship between WMH and GPR, clini¬
cal neuropsychological impression,
overall neurologic disability, severity of
illness, or serostatus. We did find, how¬
ever, that WMH increased with age and
that they were seen in association with
increased atrophy in the HIV-negative
gay men. A similar increase in WMH
with age has been noted in the generalpopulation3' and the increased age (al¬
though not statistically significant) of
the HIV-negative gay men may be con¬
founding the finding in this group. In
a prospective study, McArthur et al'
noted frequencies of white-matter ab¬
normalities among HIV-negative
(24%), asymptomatic HIV-positive(26%), and symptomatic HIV-positive(17%) subjects similar to those in this
study. They found no correlations be¬
tween clinical findings or CD4 counts
and WMH. In unselected subjects with
serial scans, they found no interval
changes in WMH in either HIV-nega¬
tive or HIV-positive subjects and con¬
cluded that those were probably inci¬
dental findings of no clinical
significance. Likewise, no differences in
the frequency of WMH across stages of
HIV infection from seronegative sub¬jects to CDC stages II, III, and IV were
seen by Levin et al.88 Foci of increased
signal were noted in four of 15 asymp¬
tomatic HIV-positive subjects without
relation to age, sex, risk group, or CD4
count by Trotot et al.39 In light of these
reports, and the lack of clinical neuro¬
logic or neuropsychologic correlates to
these WMH, we suspect that they are
not clinically meaningful. However,
Post et al" found WMHs in 17% of their
prospectively studied HIV-positive
subjects. They noted WMH to be more
extensive and more frequent in neuro-
logically symptomatic subjects, and
that led them to suggest that these were
HIV-related changes. Hopefully, serial
scans and pathologic findings will pro¬
vide a definitive conclusion.
We did not appreciate any examples
of the lesion described by Kieburtz et
al41 (concerning an area of WMH in the
corpus callosum and fornix); however,
there were many differences between
their study and ours: their study was
retrospective, had a population selected
for CNS complaints, and lacked HIV-
negative control subjects. Further¬
more, differences between our results
and those of other investigators with
regard to the presence or absence of
WMH may reflect differing imaging
techniques. The use of a 1.5-tesla MRI
scanner provides high signal detection
and resolution capabilities. On the other
hand, the absence of
 ,-weighted or pro¬
ton-density images may limit our ability
to fully characterize signal abnor¬
malities.
Atrophy seen on computed tomo¬
graphic scans was predictive of clinical
progression in one study of patients
with AIDS,1 and it has been noted as a
common finding in retrospective MRI
studies.3"6 In a prospective MRI study of
HIV-positive subjects, Post et al4" noted
an association between the presence of
cortical atrophy and abnormalities on
neurologic examination, CD4 counts
less than 400/mm3, serum p24 antigen
greater than 20 pg/mL, and elevated
p24 and IgG levels in CSF. The authors
caution, however, that atrophy based
on observer ratings is subject to vari¬
ability, as well as differing definitions of
MR abnormalities by different observ¬
ers. This latter caveat may explain the
fact that they found atrophy to be pre¬
sent in only 8% oftheir sample, while we
found at least a minor degree of atrophy
to be nearly universal. In our study, all
scans were rated by the same neurora-
diologist (J.B.) blind to HIV status and
clinical data except for age. Atrophy,
while seen more commonly in the gay
men, did not correlate with any of the
neurologic, neuropsychologic, or medi¬
cal variables in subjects without AIDS.
Finding atrophy more commonly in
the gay men seems almost counterintui¬
tive. The gay men had significantly bet¬
ter neuropsychologic performance and
fewer neurologic abnormalities than the
did the PDU cohort. In addition, one
might suspect that alcohol use and head
injury, as well as parenteral drug use,
would be more common in the PDU
group and might conceivably contribute
to atrophy on MRI scans. Yet, we found
no relationship between atrophy and
the neurologic or neuropsychologic find¬
ings and the alcohol issue becomes quite
complex when one considers that absti¬
nent alcoholics show reversal of brain
atrophy on MRI.42 Furthermore, the ef¬
fect, if any, of parenteral drug use on
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cerebral atrophy is unclear.
Neither atrophy nor WMH seen on
routine MRI distinguished HIV-posi¬
tive from HIV-negative subjects. Only
the few cases with AIDS defining le¬
sions clearly distinguished HIV-posi¬
tive from HIV-negative subjects. Real¬
izing that the neurologic and
neuropsychologic changes noted early
in HIV infection are subtle, we sought a
finer gauge for atrophy in addition to
subjective rating by a trained observ¬
er—a computer-generated calculation
of %CSF in a manually traced region of
interest produced a quantitative mea¬
sure of atrophy. Others*' have shown
such measurements to vary with age in
normal subjects. Levin et al3" in a study
of 32 subjects noted increased %CSF in
subjects with stage IV disease (per the
Centers for Disease Control criteria)
compared with others and also noted
slower simple reaction times, slower
performance on the trails  test, and
poorer performance on the Benton visu¬
al retention test with increasing %CSF
In our study, atrophy rating did not
correlate significantly with age, sug¬
gesting that our subjective ratings of
atrophy were valid for the subject's age.
That %CSF correlated with atrophy
rating, particularly when controlled for
age, further supports our notion that
the subjective atrophy ratings were val¬
id for the subject's age. The finding that
age-adjusted %CSF values correlated
inversely with CD4 counts and
CD4/CD8 ratios suggests that there is
loss ofbrain volume and replacement by
CSF in association with progression of
HIV infection (as measured by CD4
counts) independent of, or preceding,
clinical neurologic or neuropsychologic
effects. Whether this may be due to di¬
rect viral effects, toxic effects of viral
proteins, activation of other infectious
agents, or activation of neuronal genes
or autoimmune or other phenomena re¬
mains unknown.
We conclude that routine MRI of the
brain in asymptomatic and mildly symp¬
tomatic individuals with HIV infection
is not different from noninfected indi¬
viduals in similar risk groups. Further,
we speculate that quantitative mea¬
sures of atrophy that correlate with im¬
munologie measures may demonstrate
differences between HIV-positive and
HIV-negative subjects. Follow-up
scans to assess the interval changes in
CSF volumes and their relationship to
HIV-related neurologic disease may
help to define such differences.
This study was supported by federal grant P50-1-
MH43520 and additionally by'grant MH44959.
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